Education
About Us
Working with TipRanks
Follow Us
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
OVID Stock Chart & Stats
$1.59
-$0.03(-2.93%)
At close: 4:00 PM EST
$1.59
-$0.03(-2.93%)
Day’s Range― - ―
52-Week Range$0.24 - $2.01
Previous CloseN/A
Volume22.63K
Average Volume (3M)1.48M
Market Cap
$206.99M
Enterprise Value$94.27M
Total Cash (Recent Filing)$25.60M
Total Debt (Recent Filing)$13.76M
Price to Earnings (P/E)―
Beta2.34
Next Earnings
Mar 16, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding130,184,360
10 Day Avg. Volume1,943,550
30 Day Avg. Volume1,477,702
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.97
Price to Sales (P/S)116.97
P/FCF Ratio-1.18
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue14.26
Enterprise Value/Gross Profit14.30
Enterprise Value/Ebitda-2.34
Forecast
1Y Price Target
$3.60Price Target Upside126.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital And Development RunwayRecent financing strengthened the company's capital position and provides runway to initiate OV329 Phase 2a and progress near-term KCC2 candidates toward proof of concept.
Clinical DataPhase 1 biomarker and safety data for OV329 indicate de-risking of clinical development and support advancement into a randomized Phase 2a study.
KCC2 ProgramFirst human data for KCC2 activators showed a clean safety profile and central biomarker activity, highlighting a novel mechanism that could expand treatment options for intractable seizures.
Bears Say
Historical Program RiskA track record of multiple late-stage program failures increases execution risk and may keep investor confidence muted until clear clinical success is demonstrated.
Lead Molecule UncertaintyPlans to switch to a different lead molecule suggest unresolved small-molecule off-target or potency concerns, adding uncertainty to the development pathway.
Safety RiskKey risk remains the potential for unexpected safety signals such as retinal toxicity with OV329, which could derail development and limit physician and regulator uptake.
Ovid Therapeutics News
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $2.01 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Ovid Therapeutics Inc’s market cap is $206.99M.
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is Mar 16, 2026 which is in 30 days.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.02.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 130,184,360 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Currently, no hedge funds are holding shares in OVID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ovid Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.60 (126.42% Upside)
$3.60 (126.42% Upside)
Blogger Sentiment
Bullish
OVID Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.52%
12-Months-Change
Fundamentals
Return on Equity
-60.06%
Trailing 12-Months
Asset Growth
-37.80%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID Stock 12 Month Forecast
Average Price Target
$3.60
▲(126.42% Upside)
Technical Analysis
Opus Genetics
―
Zentalis Pharmaceuticals
―
Inhibikase Therapeutics
―
Surrozen
―
Biomea Fusion
―
Ownership Overview
17.79% Insiders
10.49% Mutual Funds
0.91% Other Institutional Investors
66.95% Public Companies and Individual Investors